CXCL11/I-TAC Antibody (Mouse mAb) [F19K22]

Application: Reactivity: Mouse

Usage Information

Dilution
WB1:1000

Application
WB

Reactivity
Mouse

Source
Mouse Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
11 kDa

Datasheet & SDS

Biological Description

Specificity
CXCL11/I-TAC Antibody (Mouse mAb) [F19K22] detects endogenous levels of total CXCL11/I-TAC protein.

Clone
F19K22

Synonym(s)
beta-R1, H174, I-TAC, ITAC, SCYB9B

Background
CXCL11, also known as I-TAC or IP-9, is an interferon-inducible CXC chemokine belonging to the ELR-negative CXCL9/10/11 subfamily. It functions as a high-affinity ligand for the chemokine receptor CXCR3, with additional activity at CXCR7 and antagonist properties at CCR5. CXCL11 is produced as a small secreted protein with the conserved N-terminal CXC motif and typical chemokine fold, forming a compact β-sheet–helix structure whose surface residues define selective interactions with CXCR3 and distinguish its receptor binding and signaling profile from those of the related ligands CXCL9 and CXCL10. Subtle differences in the N-loop and 30s/40s loops underlie its particularly strong CXCR3 engagement and biased receptor activation. Gene expression of CXCL11 is strongly induced by interferon-γ and interferon-β and more weakly by interferon-α, with synergistic enhancement by inflammatory stimuli such as LPS, IL-1β, and TNF-α, leading to robust production in monocytes/macrophages, endothelial cells, keratinocytes, astrocytes, fibroblasts, hepatocytes, and other stromal and parenchymal cells during Th1-type responses and endotoxemia. Secreted CXCL11 binds CXCR3 on activated, but not naïve, T cells and on NK cells, triggers G-protein–dependent calcium flux, and drives chemotaxis of activated T lymphocytes in vitro and in vivo, positioning it as a key organizer of effector T-cell recruitment into inflamed tissues, including the central nervous system during experimental autoimmune encephalomyelitis, where CXCL11 expression follows CXCR3 up-regulation and contributes to the accumulation of Th1 cells in lesions. CXCL11–CXCR3 interactions can reshape adaptive responses: epidermal expression of CXCL11 in leishmaniasis skews local immunity toward a Th2-type profile by reducing IL-12 production by dendritic cells in draining lymph nodes, while CXCL11, acting through CXCR3, also supports the differentiation or repolarization of IL-10–high regulatory T-cell subsets, indicating that this ligand can reinforce inflammatory Th1 trafficking or instruct regulatory and Th2-biased outcomes depending on context. CXCL11 is also a natural antagonist for CCR5 and a ligand for CXCR7, expanding its influence to the modulation of leukocyte responsiveness to other chemokine axes and potentially affecting HIV coreceptor usage, angiogenesis, and tissue remodeling. Elevated CXCL11 is associated with a variety of inflammatory and immune-mediated conditions, including CNS inflammation, infectious diseases such as RSV and influenza, allergic and cutaneous disorders where keratinocyte CXCL11 expression tracks with epidermal T-cell infiltrates, and cardiovascular disease where CXCL11, together with CXCL9 and CXCL10, serves as a biomarker candidate for heart failure and left ventricular dysfunction.

Background

CXCL11, also known as I-TAC or IP-9, is an interferon-inducible CXC chemokine belonging to the ELR-negative CXCL9/10/11 subfamily. It functions as a high-affinity ligand for the chemokine receptor CXCR3, with additional activity at CXCR7 and antagonist properties at CCR5. CXCL11 is produced as a small secreted protein with the conserved N-terminal CXC motif and typical chemokine fold, forming a compact β-sheet–helix structure whose surface residues define selective interactions with CXCR3 and distinguish its receptor binding and signaling profile from those of the related ligands CXCL9 and CXCL10. Subtle differences in the N-loop and 30s/40s loops underlie its particularly strong CXCR3 engagement and biased receptor activation. Gene expression of CXCL11 is strongly induced by interferon-γ and interferon-β and more weakly by interferon-α, with synergistic enhancement by inflammatory stimuli such as LPS, IL-1β, and TNF-α, leading to robust production in monocytes/macrophages, endothelial cells, keratinocytes, astrocytes, fibroblasts, hepatocytes, and other stromal and parenchymal cells during Th1-type responses and endotoxemia. Secreted CXCL11 binds CXCR3 on activated, but not naïve, T cells and on NK cells, triggers G-protein–dependent calcium flux, and drives chemotaxis of activated T lymphocytes in vitro and in vivo, positioning it as a key organizer of effector T-cell recruitment into inflamed tissues, including the central nervous system during experimental autoimmune encephalomyelitis, where CXCL11 expression follows CXCR3 up-regulation and contributes to the accumulation of Th1 cells in lesions. CXCL11–CXCR3 interactions can reshape adaptive responses: epidermal expression of CXCL11 in leishmaniasis skews local immunity toward a Th2-type profile by reducing IL-12 production by dendritic cells in draining lymph nodes, while CXCL11, acting through CXCR3, also supports the differentiation or repolarization of IL-10–high regulatory T-cell subsets, indicating that this ligand can reinforce inflammatory Th1 trafficking or instruct regulatory and Th2-biased outcomes depending on context. CXCL11 is also a natural antagonist for CCR5 and a ligand for CXCR7, expanding its influence to the modulation of leukocyte responsiveness to other chemokine axes and potentially affecting HIV coreceptor usage, angiogenesis, and tissue remodeling. Elevated CXCL11 is associated with a variety of inflammatory and immune-mediated conditions, including CNS inflammation, infectious diseases such as RSV and influenza, allergic and cutaneous disorders where keratinocyte CXCL11 expression tracks with epidermal T-cell infiltrates, and cardiovascular disease where CXCL11, together with CXCL9 and CXCL10, serves as a biomarker candidate for heart failure and left ventricular dysfunction.

References
https://pubmed.ncbi.nlm.nih.gov/15273303/ https://pubmed.ncbi.nlm.nih.gov/15322564/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%